THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market Jury awarded ...

Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:20 a.m. ET on Wednesday, June 4, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, ...

In a study published in Nature today "Sequence diversity lost in early pregnancy," scientists from deCODE genetics, a ...

Amgen’s Philip Ryan explains his role in the ever-evolving biotech sector and why you should never be afraid to take a career ...

The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After ...

Amgen AMGN stock has risen 19.6% in the past six months compared with an increase of 12.4% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart ...

Many therapies aren't nearly as successful as hoped. Biotech giant Amgen (NASDAQ: AMGN) has had a harsh reminder of that reality in recent years. Some of its most recent brand-new launches ...

Since its founding in 1980, Amgen has devoted itself to fostering a culture of innovation. The company has routinely spent between 16% and 19% of its total revenue on research and development for ...